NZ company growing new skin for burn victims

A Kiwi biotechnology company which has found a way to grow bigger-than-A5 sheets of replacement human skin says the product might be ready to start clinical trials on burn patients in 2020 or 2021.

Upside Biotechnologies, a company which spun out of the University of Auckland’s immunology research area, announced this week it has raised $2 million in a convertible notes issue from existing investors.

And it is preparing for a $10m to $15m capital raising later this year, which will hopefully take it into clinical trials 12-15 months after that.

Read more

Upside Biotechnologies wins $409k research grant

Upside Biotechnologies, a regenerative tissue developer spun out of Auckland University, has won a $409,000 research grant to prepare its PelliCel product for a clinical trial and deepening its existing relationship with the US Army.

Auckland-based Upside, which raised $2.3 million last year, won the Medical Technology Enterprise Consortium (MTEC) prototype acceleration award, it said in a statement. The biotech firm is developing an advanced skin replacement treatment for burn victims, enabling a small sample of unburnt skin to be grown in a lab and used as skin grafts for patients who don’t have enough uninjured skin for a conventional graft.

Read more

Lead Partners

NZTE NZGCP PWC ATEED “NZX”

Expert Partner

AVID “Jarden” Baldwins

AANZ Summit Sponsors

“UniServices” Kiwinet “AWS” “BNZ” “Momentum” “Hillfarrance” “Punakaiki” “MBIE” “GD1” “TompkinsWake” Callaghan Innovation